Yaz Plus FC tablets
PDF Leaflet Revision Date: 12 May 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Oral contraception and improvement of folate status.
Dosage (summary)
One tablet daily for 28 days, starting on the first day of the menstrual period.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not indicated during pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- Enzyme inducers (e.g., phenytoin, rifampicin)
- CYP3A4 inhibitors (e.g., ketoconazole)
Contraindications
- Hypersensitivity
- Thromboembolic events
- Severe hepatic disease
- Severe renal insufficiency
- Undiagnosed vaginal bleeding
Common side effects
- Nausea
- Breast pain
- Unscheduled uterine bleeding
Counselling Points
- Take at the same time daily
- Use barrier method if pills are missed
- Not protective against STDs
Serious warnings
- Increased risk of thromboembolic events
- Monitor for mood changes
Important Disclaimer
The Yaz Plus FC tablets professional information leaflet below is the property of Bayer and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
